论文部分内容阅读
目的总结知柏地黄丸药理作用及治疗儿童过敏性紫癜的临床疗效。方法 80例过敏性紫癜患儿随机分为观察组和对照组,各40例。观察组给予知柏地黄丸联合西医常规治疗;对照组给予单纯西医常规治疗。检测治疗前后血清免疫球蛋白(Ig A、Ig G)水平和尿常规,观察两组患者治疗不良反应。结果治疗后两组的血清Ig A、Ig G水平均较治疗前明显改善,观察组改善情况明显优于对照组,差异具有统计学意义(P<0.05);治疗前两组尿常规中红细胞计数(RBC)、白细胞计数(WBC)、RBC及WBC高倍视野、治疗后两组均较治疗前明显改善,观察组改善情况明显优于对照组,差异具有统计学意义(P<0.05);两组均未发生严重不良反应。结论知柏地黄丸辅助治疗儿童过敏性紫癜能显著提高治疗效果,且安全性较高,其作用机制可能与调节免疫球蛋白水平,抑制抗原抗体反应有关。
Objective To summarize the pharmacological effects of Zhibo Di Huang Wan and the clinical effects of treating Henoch-Schonlein purpura in children. Methods 80 cases of children with Henoch-Schonlein purpura were randomly divided into observation group and control group, 40 cases in each. The observation group was given Zhibai Di Huang Wan combined with Western routine treatment; the control group was given simple western medicine routine treatment. Serum immunoglobulin (Ig A, Ig G) levels and urine routine were measured before and after treatment. Adverse reactions were observed in both groups. Results After treatment, the levels of serum Ig A and Ig G in both groups were significantly improved compared with those before treatment, and the improvement in the observation group was significantly better than that in the control group (P <0.05). Before treatment, the urinary routine red blood cell count (RBC), white blood cell count (WBC), RBC and WBC high power field. After treatment, both groups were significantly improved compared with those before treatment. The improvement in the observation group was significantly better than that in the control group (P <0.05) No serious adverse reactions occurred. Conclusion Zhibai Dihuang Pill can significantly improve the therapeutic effect of Henoch - Schonlein purpura in children and its safety is higher. Its mechanism may be related to the regulation of immunoglobulin levels and the inhibition of antigen - antibody reaction.